We analyzed the downregulation of co-stimulatory molecules such as TNFRSF and TNFRSF4 in the C2 subtype, which may weaken T-cell activation and immune effects in the tumor microenvironment, thereby partially explaining why the immune efficacy remains poor despite high PD-L1 expression. The gene discussed is TNFRSF4; the disease is neoplasm.